{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Oral+Cavity+Cancer+AJCC+v6+and+v7",
    "query": {
      "condition": "Stage II Oral Cavity Cancer AJCC v6 and v7"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:16:01.013Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02381561",
      "title": "Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Bile Duct Carcinoma",
        "Stage II Esophageal Cancer AJCC v7",
        "Stage II Pancreatic Cancer AJCC v6 and v7",
        "Stage IIA Esophageal Cancer AJCC v7",
        "Stage IIA Pancreatic Cancer AJCC v6 and v7",
        "Stage IIB Esophageal Cancer AJCC v7",
        "Stage IIB Pancreatic Cancer AJCC v6 and v7",
        "Stage III Colon Cancer AJCC v7",
        "Stage III Esophageal Cancer AJCC v7",
        "Stage III Gastric Cancer AJCC v7",
        "Stage III Liver Cancer",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage III Rectal Cancer AJCC v7",
        "Stage III Small Intestinal Cancer AJCC v7",
        "Stage IIIA Colon Cancer AJCC v7",
        "Stage IIIA Esophageal Cancer AJCC v7",
        "Stage IIIA Gastric Cancer AJCC v7",
        "Stage IIIA Rectal Cancer AJCC v7",
        "Stage IIIA Small Intestinal Cancer AJCC v7",
        "Stage IIIB Colon Cancer AJCC v7",
        "Stage IIIB Esophageal Cancer AJCC v7",
        "Stage IIIB Gastric Cancer AJCC v7",
        "Stage IIIB Rectal Cancer AJCC v7",
        "Stage IIIB Small Intestinal Cancer AJCC v7",
        "Stage IIIC Colon Cancer AJCC v7",
        "Stage IIIC Esophageal Cancer AJCC v7",
        "Stage IIIC Gastric Cancer AJCC v7",
        "Stage IIIC Rectal Cancer AJCC v7",
        "Stage IV Colon Cancer AJCC v7",
        "Stage IV Esophageal Cancer AJCC v7",
        "Stage IV Gastric Cancer AJCC v7",
        "Stage IV Liver Cancer",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IV Rectal Cancer AJCC v7",
        "Stage IV Small Intestinal Cancer AJCC v7",
        "Stage IVA Colon Cancer AJCC v7",
        "Stage IVA Liver Cancer",
        "Stage IVA Rectal Cancer AJCC v7",
        "Stage IVB Colon Cancer AJCC v7",
        "Stage IVB Liver Cancer",
        "Stage IVB Rectal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Ropidoxuridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2016-02-01",
      "completion_date": "2027-03-14",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02381561"
    },
    {
      "nct_id": "NCT03468218",
      "title": "Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Head and Neck Carcinoma",
        "Paranasal Sinus Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Unresectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2018-09-18",
      "completion_date": "2026-10-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Atlanta, Georgia",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03468218"
    },
    {
      "nct_id": "NCT02595879",
      "title": "Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cervical Adenocarcinoma",
        "Advanced Cervical Adenosquamous Carcinoma",
        "Advanced Cervical Squamous Cell Carcinoma",
        "Advanced Vaginal Adenocarcinoma",
        "Advanced Vaginal Adenosquamous Carcinoma",
        "Advanced Vaginal Squamous Cell Carcinoma",
        "Stage IB2 Cervical Cancer AJCC v6 and v7",
        "Stage II Cervical Cancer AJCC v7",
        "Stage II Vaginal Cancer AJCC v6 and v7",
        "Stage III Vaginal Cancer AJCC v6 and v7",
        "Stage IIIB Cervical Cancer AJCC v6 and v7",
        "Stage IVA Cervical Cancer AJCC v6 and v7",
        "Stage IVA Vaginal Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "High-Dose Rate Brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Triapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2019-09-18",
      "completion_date": "2026-04-29",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Pasadena, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595879"
    },
    {
      "nct_id": "NCT01810913",
      "title": "Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma",
        "Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 613,
      "start_date": "2013-03-22",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 338,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01810913"
    },
    {
      "nct_id": "NCT02917629",
      "title": "ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Cavity Neoplasm",
        "Oropharyngeal Neoplasm",
        "Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7",
        "Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2018-05-31",
      "completion_date": "2019-08-28",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Minneapolis, Minnesota • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02917629"
    },
    {
      "nct_id": "NCT03220009",
      "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Carcinoma",
        "Esophageal Carcinoma",
        "Mucosal Melanoma",
        "Mucosal Melanoma of the Head and Neck",
        "Oral Cavity Mucosal Melanoma",
        "Recurrent Melanoma",
        "Stage II Vulvar Cancer AJCC v7",
        "Stage III Vulvar Cancer AJCC v7",
        "Stage IIIA Vulvar Cancer AJCC v7",
        "Stage IIIB Vulvar Cancer AJCC v7",
        "Stage IIIC Vulvar Cancer AJCC v7",
        "Stage IV Oral Cavity Cancer AJCC v6 and v7",
        "Stage IV Vulvar Cancer AJCC v7",
        "Stage IVA Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVB Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVC Oral Cavity Cancer AJCC v6 and v7",
        "Vaginal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2017-11-03",
      "completion_date": "2021-07-01",
      "has_results": false,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220009"
    },
    {
      "nct_id": "NCT03012100",
      "title": "Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bilateral Breast Carcinoma",
        "Breast Inflammatory Carcinoma",
        "Stage IB Breast Cancer AJCC v7",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Triple-Negative Breast Carcinoma",
        "Unilateral Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Multi-epitope Folate Receptor Alpha Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 280,
      "start_date": "2017-03-31",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-13",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03012100"
    },
    {
      "nct_id": "NCT01604772",
      "title": "Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Oral Cavity Adenoid Cystic Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Salivary Gland Adenoid Cystic Carcinoma",
        "Stage IVA Major Salivary Gland Cancer AJCC v7",
        "Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7",
        "Stage IVB Major Salivary Gland Cancer AJCC v7",
        "Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7",
        "Stage IVC Major Salivary Gland Cancer AJCC v7",
        "Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Akt Inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2012-07-23",
      "completion_date": "2014-11-22",
      "has_results": true,
      "last_update_posted_date": "2019-05-01",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 51,
      "location_summary": "Lewes, Delaware • Newark, Delaware • Jacksonville, Florida + 36 more",
      "locations": [
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01604772"
    },
    {
      "nct_id": "NCT01365169",
      "title": "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Head and Neck Neoplasm",
        "Malignant Neoplasm",
        "Metastatic Malignant Neoplasm in the Neck",
        "Metastatic Malignant Neoplasm in the Uterine Cervix",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Stage I Colorectal Cancer AJCC v6 and v7",
        "Stage I Hypopharyngeal Carcinoma AJCC v7",
        "Stage I Major Salivary Gland Cancer AJCC v7",
        "Stage I Nasopharyngeal Carcinoma AJCC v7",
        "Stage I Oral Cavity Cancer AJCC v6 and v7",
        "Stage I Oropharyngeal Carcinoma AJCC v6 and v7",
        "Stage II Colorectal Cancer AJCC v7",
        "Stage II Hypopharyngeal Carcinoma AJCC v6 and v7",
        "Stage II Major Salivary Gland Cancer AJCC v7",
        "Stage II Nasopharyngeal Carcinoma AJCC v7",
        "Stage II Oral Cavity Cancer AJCC v6 and v7",
        "Stage II Oropharyngeal Carcinoma AJCC v6 and v7",
        "Stage IIA Colorectal Cancer AJCC v7",
        "Stage IIB Colorectal Cancer AJCC v7",
        "Stage IIC Colorectal Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Hypopharyngeal Carcinoma AJCC v7",
        "Stage III Laryngeal Cancer AJCC v6 and v7",
        "Stage III Major Salivary Gland Cancer AJCC v7",
        "Stage III Nasopharyngeal Carcinoma AJCC v7",
        "Stage III Oral Cavity Cancer AJCC v6 and v7",
        "Stage III Oropharyngeal Carcinoma AJCC v7",
        "Stage IIIA Colorectal Cancer AJCC v7",
        "Stage IIIB Colorectal Cancer AJCC v7",
        "Stage IIIC Colorectal Cancer AJCC v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVA Hypopharyngeal Carcinoma AJCC v7",
        "Stage IVA Laryngeal Cancer AJCC v7",
        "Stage IVA Major Salivary Gland Cancer AJCC v7",
        "Stage IVA Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVA Oropharyngeal Carcinoma AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7",
        "Stage IVB Hypopharyngeal Carcinoma AJCC v7",
        "Stage IVB Laryngeal Cancer AJCC v7",
        "Stage IVB Major Salivary Gland Cancer AJCC v7",
        "Stage IVB Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVB Oropharyngeal Carcinoma AJCC v7",
        "Metastatic or Locally Unresectable Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health Telemonitoring",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2011-05-25",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365169"
    },
    {
      "nct_id": "NCT03575234",
      "title": "Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
        "Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "IRX-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-07-01",
      "completion_date": "2026-01-31",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-05-22T02:16:01.013Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03575234"
    }
  ]
}